Gustave Roussy Cancer Profiling
ConditionSolid Tumor, Unspecified, Adult
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorGustave Roussy, Cancer Campus, Grand Paris
About this trial
The objective of STING study is to perform high throughput molecular analysis (next generation sequencing +/- immunological profiling) to estimate the proportion of patients with cancer presenting at least one targetable genomic alteration.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥ 18 years
Histology: solid malignant tumor or hematological malignancy.
Patient with a social security in compliance with the French law relating to biomedical research (Article L.1121-11 of French Public Health Code)
Voluntary signed and dated written informed consent prior to any study specific procedure.
Disqualifiers
Any condition which in the Investigator's opinion makes it undesirable for the subject to participate in a clinical trial or which would jeopardize compliance with the protocol
Patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving its consent
Pregnant or breast-feeding women
Minors (Age < 18 years)
Trial design
Design model
Single group
Treatments tested in this trial
Biopsy
Procedure/SurgeryBlood and tumor samples for Genetic Profiling research
Treatment groups
20,000 Participants
are divided into 1 treatment groupGroup A: solid tumor or hematological malignancyExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Number of patients presenting at least one targetable genomic alteration
Number of patients presenting at least one targetable genomic alteration
Time frame
2 months after the last enrollment2
Proportion of patients presenting at least one targetable genomic alteration
Proportion of patients presenting at least one targetable genomic alteration
Time frame
2 months after the last enrollmentSecondary outcomes
1
Rate of molecular profiling information including utilization of information for standard regimens or clinical trials of molecularly targeted therapies
For a patient with molecular results available utilization of molecular profiling information is defined as Inclusion in a clinical trial assessing a drug matched to the molecular alteration And/or Treatment with an approved drug matched with the molecular alteration
Time frame
2 months after the last enrollment2
Objective response rate
Time frame
24 months post treatment after the last enrollment3
Progression-free survival
Time frame
24 months post treatment after the last enrollment4
Overall survival
Time frame
24 months post treatment after the last enrollmentSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov